Background: New metrics generated by Continuous Glucose Monitoring (CGM) have highlighted the importance of glucose variability, measured as coefficient of variation. It is also suggested that CV may be a more accurate measure to assess time spent in hypoglycemia, as opposed to A1c. This association in older adults is not well studied.

Methods: Older adults (age ≥65 years) with T1D underwent 2 weeks of CGM. Based on the international consensus, CV was calculated by dividing standard deviation of glucose by mean glucose from CGM. The participants were stratified by CV ≤ 36%, or >36%. Duration of clinically significant hypoglycemia (glucose level ≤ 54 mg/dl) and A1c were measured.

Results: We evaluated 76 older adults (mean age 71 years, duration of T1D 39 years, 62% on insulin pump, and 38% on multiple daily injections (MDI)). In participants with CV ≤36% (n=19, 25%), A1c was 6.8±0.8%, and they spent 9.6 min/day in hypoglycemia, while in those with CV>36% (n=57, 75%), A1c was 7.5±0.8%, and they spent 43 min/day in hypoglycemia (p=0.003 and p<0.0001, respectively). In participants with CV>36%, those using MDI had longer duration of hypoglycemia compared to those using insulin pump (61 minutes/day vs. 33 minutes/day, p=0.03), despite similar A1c (7.5% in both groups).

Conclusion: In our cohort of older adults with T1D, CV>36% is associated with higher duration of hypoglycemia despite higher A1c. Keeping CV value <36% in a vulnerable population may help mitigate risk of hypoglycemia independent of A1c value.


E. Toschi: Advisory Panel; Self; Lexicon Pharmaceuticals, Inc. C. Slyne: None. A.B. Dufour: None. A. Atakov-Castillo: None. S. Carl: None. K. Sifre: None. J. Greenberg: None. M. Munshi: Consultant; Self; Lilly Diabetes, Sanofi.


National Institute of Diabetes and Digestive and Kidney Diseases

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at